Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Feb 28, 2011

165_ip_2011-02-28_17a0c191-7779-496f-ac7c-b0583a2e61e7.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Fiscal Year 2010

Analyst Conference February 23, 2011

AGENDA

1 BUSINESS UPDATE

2 FINANCIALS & OUTLOOK

3 QUESTIONS & ANSWERS

BUSINESS UPDATE

1

Q4 and Fiscal Year 2010

© I Analyst Conference I Full Year 2010 3

Fiscal Year −Overview

Record Results for 2010

  • XAchieved revenue guidance and upper end of net income guidance
  • XRevenue growth of 7% at constant currency
  • XOrganic revenue growth of 6%
  • XAdvanced global strategy
\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 G
i
d
u
a
n
c
e
2
0
1
0		 F
Y
2
0
1
0		 G
h
i
%
t
r
o
w
n
N
R
t
e
e
v
e
n
u
e		 1
2
0
0
0
>
,		 1
2,
0
5
3		 7
N
i
t
e
n
c
o
m
e
t
tr
i
bu
ta
b
le
to
F
M
C
A
G
&
Co
K
Ga
A
a
,		 9
6
0
9
8
0
-		 9
9
7		 1
0
C
i
t
l
d
i
t
a
p
a
e
p
e
n
r
e
x
u		 5
5
0
6
5
0
-		 5
0
7
A
i
i
t
i
c
q
s
o
n
s,
f
u
t o
d
ive
t
i
tu
n
e
s
re
s		 t
5
0
0
p
o
u		 6
1
8
L
i
t
e
v
e
r
a
g
e
r
a
o
(
De
b
/
E
b
i
da
l
ip
le
)
t
t
t
m
u		 2
5
<		 2.
3
8

Total revenue improved 7% to \$ 12,053 million

Q4 − Overview

Excellent finish of the fiscal year 2010

  • XRevenue growth of 5% at constant currency
  • XImpressive earnings development
\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 Q
4
2
0
0
9		 Q
4
2
0
1
0		 G
h
i
%
t
r
o
w
n
N
R
t
e
e
v
e
n
u
e		 3,
0
3
5		 3,
1
6
7		 4
O
i
i
(
E
B
I
T
)
t
p
e
r
a
n
g
n
c
o
m
e		 4
9
1		 5
3
9		 1
0
N
t
i
e
n
c
o
m
e
t
tr
i
bu
ta
b
le
to
F
M
C
A
G
&
Co
K
Ga
A
a
,		 2
4
7		 2
7
1		 1
0
E
i
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 0
8
2		 0.
9
0		 9

Q4 − Revenue split by region

Total revenue improved 4% to \$ 3,167 million

Q4 − Dialysis Services

Strong global revenue growth

  • XContinued impressive same market growth + 5%
  • XExcellent organic revenue growth in International + 8%
  • XUSA preparing for the "bundle"
cc
=		 tan
t c
co
ns
urr
en
cy
T
l
t
o
a		 2,
2
2
6		 2,
3
5
4		 6 6 4.
1		 5.
0
I
i
l
t
t
n
e
r
n
a
o
n
a		 4
2
7		 4
9
2		 1
5		 1
8		 8
0		 6
2
N
h
A
i
t
o
r
m
e
r
c
a		 1,
7
9
9		 1,
8
6
2		 3 3 3
3		 4
4
\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 Q
4
2
0
0
9		 Q
4
2
0
1
0		 G
h
t
r
o
w
i
%
n		 G
h
t
r
o
w
i
%
n
c
c		 O
i
r
g
a
n
c
h
t
g
r
o
w
i
%
n		 S
a
m
e
k
t
m
a
r
e
h
t
g
r
o
w
i
%
n

8© I Analyst Conference I Full Year 2010

Fiscal Year−Dialysis Services

Outstanding growth globally

  • XDelivered nearly 32.000.000 treatments globally + 8%
  • XProviding care to nearly 215.000 patients globally +10%
  • XRepresented with 2.757 dialysis clinics worldwide + 8%
  • XExcellent organic revenue growth + 7%
cc
co
=		 tan
t c
ns
urr
en
cy
T
l
t
o
a		 5
8,
3
0		 9,
0
7
0		 9 9 6.
6		 4.
6
I
t
t
i
l
n
e
r
n
a
o
n
a		 1,
5
5
6		 1,
7
6
7		 1
4		 1
3		 6
3		 5
1
N
t
h
A
i
o
r
m
e
r
c
a		 6,
7
9
4		 7,
3
0
3		 7 7 6
7		 4
3
\$
S
U
i
i
l
l
i
n
m
o
n
s
-		 F
Y
2
0
0
9		 F
Y
2
0
1
0		 G
t
h
r
o
w
%
i
n		 G
t
h
r
o
w
%
i
n
c
c		 O
i
r
g
a
n
c
t
h
g
r
o
w
%
i
n		 S
a
m
e
k
t
m
a
r
e
t
h
g
r
o
w
%
i
n

Q4 − Dialysis Services│Quality outcomes

U
i
d
t
n
e		 S
t
t
a
e
s		 E
M
E
A
Q Q Q Q
4 4 4 4
2 2 2 2
0 0 0 0
0 1 0 1
9 0 9 0
9 9 9 9
6 7 5 5
6 1 5 5
4 7 2 4
7 7 1
1		 1
2
8 8 8 8
3 4 6 6
5 5 6 5
5 7 1 9
7 7 8 8
3 6 3 2
1
0
0		 9.
9		 8
6		 9.
7

Q4│FY − Dialysis Services│Revenue per treatment US

359

+3%

355

356

Q3

Q4

Average

Q4 − Dialysis Products

Above market growth for total product revenue at +6%cc with accelerating acquisitions

XAsia-Pacific revenue growth of 11%cc

\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 Q
4
2
0
0
9		 Q
4
2
0
1
0		 G
t
h
r
o
w
i
%
n		 G
t
h
r
o
w
i
%
n
c
c
T
l
d
t
t
o
a
p
r
o
u
c
r
e
v
e
n
u
e
(
inc
l.
In
l
)
te
rn
a		 1,
0
7
5		 1,
1
1
7		 4 6
E
l
R
t
x
e
r
n
a
e
v
e
n
u
e		 8
0
9		 8
1
3		 - 3
N
h
A
i
t
o
r
m
e
r
c
a		 2
1
3		 2
1
0		 (
1
)		 (
1
)
I
i
l
t
t
n
e
r
n
a
o
n
a		 5
9
6		 6
0
3		 1 4
cc
=		 tan
t c
co
ns
urr
en
cy

12© I Analyst Conference I Full Year 2010

Fiscal Year −Dialysis Products

In line with expectations

  • XTotal revenue growth of 5%
  • XInternational sales grew at 4%
  • XDouble digit sales growth in Asia-Pacific of 12%cc
\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 F
Y
2
0
0
9		 F
Y
2
0
1
0		 G
h
t
r
o
w
i
%
n		 G
h
t
r
o
w
i
%
n
c
c
T
l
d
t
t
o
a
p
r
o
u
c
r
e
v
e
n
u
e
(
inc
l.
In
te
l
)
rn
a		 3,
8
9
1		 4,
0
9
8		 5 5
E
t
l
R
e
r
n
a
e
e
n
e
x
v
u		 2
8
9
7
,		 2,
9
8
3		 3 3
N
t
h
A
i
o
r
m
e
r
c
a		 8
1
8		 8
2
7		 1 1
I
t
t
i
l
n
e
r
n
a
o
n
a		 2
0
7
9
,		 2,
1
5
6		 4 4
cc
=		 tan
t c
co
ns
urr
en
cy

2010 −Annual Dividend Proposal

14th consecutive dividend increase

  • XDividend up 7% versus 2009
  • XEPS growth of 9% for 2010

14© I Analyst Conference I Full Year 2010

GOAL 10 −Long-term target overachieved

15© I Analyst Conference I Full Year 2010

© I Analyst Conference I Full Year 2010 16

2010│2011− Expansion & Product Launches

Drivers for sustained revenue and earnings growth

Expansion

  • X Acquisition of Asia Renal Care with more than 100 clinics
  • X Strengthened our leadership position by acquiring the largest service provider in Asia-Pacific outside of Japan

XAcquisition of Gambro-PD-business

X Improves our market position in Asia-Pacific and Europe with a complementary products and technology portfolio

XJoint venture with Galenica

  • XPhase 1 closed in December 2010
  • X Combines the global leaders to develop improved therapies for CKD patients suffering from iron deficiency, anemia and bone mineral metabolism

XAcquisition of Euromedic dialysis services

  • XImproves our market position and achieves critical scale of our clinic network in Eastern Europe
  • XExpected close late Q2 | 2011

2010│2011− Expansion & Product Launches

Drivers for sustained revenue and earnings growth

New renal product launches

2010 −Summary

Leadership

  • XMaintain global leadership position
  • XContinue to shape the future of the dialysis industry

Quality

XContinue focusing on superior quality in services and products

Growth

  • XBenefit from product innovations and new product launches
  • XTake advantage of international growth potential and introduce new therapy offerings
  • XContinue horizontal expansion of service and product range

Financials

  • XControl costs and spending and continue profitable growth momentum
  • XSeek attractive investment opportunities

FINANCIALS & OUTLOOK

Q4 and Fiscal Year 2010

© I Analyst Conference I Full Year 2010 20

Q4 − Profit & Loss

\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 Q
4
2
0
0
9		 Q
4
2
0
1
0		 G
h
t
r
o
w
i
%
n
N
t
R
e
e
e
n
e
v
u		 3,
0
3
5		 3,
1
6
7		 4 %
5
c
c
O
(
)
t
i
i
E
B
I
T
p
e
r
a
n
g
n
c
o
m
e		 4
9
1		 5
3
9		 1
0
E
B
I
T-
i
i
%
m
a
r
g
n
n		 1
6
2		 1
7.
0
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e
n
e
,		 7
5		 7
4
I
b
f
t
n
c
o
m
e
e
o
r
e
a
x
e
s		 4
1
6		 5
4
6		 1
2
I
t
n
c
o
m
e
a
x
e
x
p
e
n
s
e		 1
4
5		 1
6
9
T
i
%
t
a
x
r
a
e
n		 3
5		 3
6
N
t
l
l
i
i
t
t
o
n-
c
o
n
r
o
n
g
n
e
r
e
s		 2
4		 2
5
N
t
i
e
n
c
o
m
e
att
rib
uta
ble
to
FM
C A
G
& C
KG
aA
o.		 2
4
7		 2
1
7		 1
0

Fiscal Year −Profit & Loss

F
Y
2
0
0
9		 F
Y
2
0
1
0		 G
t
h
r
o
w
%
i
n
1
1,
2
4
7		 1
2,
0
5
3		 7 7
%
c
c
1,
6
7
5		 1,
9
2
4		 1
0
1
6
5		 1
6.
0		 4
0
b
p
s
i
t
m
p
r
o
e
m
e
n
v
3
0
0		 2
8
0
1,
4
6
5		 1,
6
4
4		 1
3
4
9
1		 5
8
7
3
4		 3
5
7
4		 8
7
8
9
1		 9
7
9		 1
0

23© I Analyst Conference I Full Year 2010

Q4 − Cash Flow

O
i
C
h
F
l
4
5
8
3
4
1
(
2
6
)
t
p
e
r
a
n
g
a
s
o
w
%
f
1
5
1
1
o
r
e
v
e
n
u
e
C
i
l
E
d
i
(
1
7
3
)
(
1
6
8
)
t
t
t
a
p
a
x
p
e
n
u
r
e
n
e
,
F
h
f
l
2
8
5
1
7
3
(
3
9
)
r
e
e
c
a
s
o
w
%
f
9
5
o
r
e
e
n
e
v
u
f
(
)
(
)
A
i
i
t
i
t
d
i
t
i
t
7
9
3
7
9
c
q
s
o
n
s,
n
e
o
e
s
r
e
s
u
v
u
f
f
2
0
6
(
)
F
h
l
t
i
i
t
i
2
0
6
r
e
e
c
a
s
o
w
a
e
r
a
c
q
u
s
o
n
s
%
f
7
o
r
e
v
e
n
u
e		 \$
S
U
i
i
l
l
i
n
m
o
n
s
-		 Q
4
2
0
0
9		 Q
4
2
0
1
0		 G
t
h
r
o
w
%
i
n

Fiscal Year −Cash Flow

1,
3
3
9
1,
3
6
8		 2
1
2		 1
1
(
6
2
)
5		 (
5
)
0
7
7
7
7		 8
6
1		 1
1
7 7
(
1
8
6
)		 (
)
6
1
8
5
9
1		 2
4
3
6 2

Fiscal Year −Total Debt/EBITDA

Achieved target to be below 2.5

XSuccessful bond placement

26© I Analyst Conference I Full Year 2010

2011−Outlook

Another record year to be expected

  • XFor 2011 strong revenue growth and further EBIT-margin improvement expected
  • XNet income guidance does not consider a correction of the "transition adjuster " for US dialysis clinics in 2011
\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 F
Y
E
2
0
1
1
N
t
R
e
e
e
n
e
v
u		 1
2,
8
0
0
1
3,
0
0
0
–
N
t
i
e
n
c
o
m
e
C
G
&
Co
Ga
t
tr
i
bu
ta
b
le
to
F
M
A
K
A
a		 5
5
5
1,
0
3
1,
0
–
C
%
f
i
t
l
d
i
t
i
a
p
a
e
p
e
n
r
e
n
o
r
e
e
n
e
x
u
v
u		 %
5
~
A
i
i
t
i
c
q
s
o
n
s
u		 1,
2
0
0
~
L
t
i
e
e
r
a
g
e
r
a
o
(
/
)
v
De
b
t
E
b
i
t
da
l
t
ip
le
m
u		 2
8
≤
cc
co
ns
=

QUESTIONS & ANSWERS

Q4 and Fiscal Year 2010

© I Analyst Conference I Full Year 2010 28

CREATING A FUTURE WORTH LIVING. FOR PEOPLE. WORLDWIDE. EVERY DAY.

Thank you very much for your attention!

Attachment 1

Reconciliation of non-US-GAAP financial measures to most comparable US-GAAP measure

Ex
l
Re
Q
4
te
rn
a
ve
nu
e		 Q
4
2
0
0
9		 Q
4
2
0
1
0		 Gr
h
in
%
t
ow		 Gr
t
in %
h
ow
In
te
t
ion
l p
du
t r
rn
a
a
ro
c
ev
en
ue		 6
9
2		 7
1
7		 4 cc
7
In
l re
te
rn
a
ve
nu
e
-		 (
9
6
)		 (
1
1
4
)
In
te
t
ion
l e
te
l re
=
rn
a
a
x
rn
a
ve
nu
e		 5
9
6		 6
0
3		 1 4
No
t
h
Am
ica
du
t r
r
er
p
ro
c
ev
en
ue		 3
8
3		 4
0
0		 4 4
In
te
l re
rn
a
ve
nu
e
-		 (
)
1
7
0		 (
)
1
9
0
No
h
Am
ica
l re
t
te
r
er
ex
rn
a
ve
nu
e
=		 2
1
3		 2
1
0		 (
1
)		 (
1
)
To
l p
du
ta
t r
ro
c
ev
en
ue		 1,
0
7
5		 1,
1
1
7		 4 6
In
te
l re
rn
a
ve
nu
e
-		 (
2
6
6
)		 (
3
0
4
)
To
l e
l r
ta
te
x
rn
a
ev
en
ue		 8
0
9		 8
1
3		 0 3
Ex
l
Re
F
isc
l
Ye
te
rn
a
ve
nu
e
a
ar		 2
0
0
9		 2
0
1
0		 Gr
%
t
h
in
ow		 Gr
t
in %
h
ow
cc
In
te
t
ion
l p
du
t r
rn
a
a
ro
c
ev
en
ue		 2,
4
2
8		 2,
5
5
3		 5 5
In
te
l re
rn
a
ve
nu
e
-		 (
)
3
4
9		 (
)
3
9
7
In
ion
l e
l re
te
t
te
rn
a
a
x
rn
a
ve
nu
e
=		 2,
0
7
9		 2,
1
5
6		 4 4
No
h
Am
ica
du
t
t r
r
er
p
ro
c
ev
en
ue		 1,
4
6
3		 1,
4
5
5		 6 6
In
te
l re
rn
a
ve
nu
e
-		 (
6
4
5
)		 (
7
1
8
)
No
t
h
Am
ica
te
l re
=
r
er
ex
rn
a
ve
nu
e		 8
1
8		 8
2
7		 1 1
To
l p
du
t r
ta
ro
c
ev
en
ue		 3,
8
9
1		 4,
0
9
8		 5 5
In
l re
te
rn
a
ve
nu
e
-		 (
9
9
4
)		 (
1,
1
1
)
5
To
l e
l r
ta
te
x
rn
a
ev
en
ue		 2,
8
9
7		 2,
9
8
3		 3 3

All numbers are in US\$ millions

Attachment 2

Reconciliation of non-US-GAAP financial measures to most comparable US-GAAP measure

Ca
i
l
Ex
d
i
ta
tu
t
p
p
en
re
ne
,		 Q
4
2
0
0
9		 Q
4
2
0
1
0		 F
Y
2
0
0
9		 F
Y
2
0
1
0
Pu
ha
f p
lan
d e
ip
ty
t a
t
rc
se
o
ro
p
er
p
n
q
me
n
u
,		 (
1
)
7
5		 (
1
4
)
7		 (
4
)
5
7		 (
2
3
)
5
Pr
ds
fro
le
f p
ty,
lan
t a
d e
ip
t
oc
ee
m
sa
o
ro
p
er
p
n
q
u
me
n
-		 2 6 1
2		 1
6
Ca
i
ta
l e
d
i
tu
t
=
p
xp
en
re
ne
,		 (
)
1
7
3		 (
)
1
6
8		 (
)
5
6
2		 (
)
5
0
7
Ca
h
F
low
s		 Q
4
2
0
0
9		 Q
4
2
0
1
0		 F
Y
2
0
0
9		 F
Y
2
0
1
0
Ac
is
i
i
ion
inv
d
ha
f
t
tm
ts
t p
q
u
s,
es
en
an
ne
ur
c
se
s o
in
ta
i
b
le
ts
ng
as
se		 (
7
9
)		 (
3
8
6
)		 (
1
8
8
)		 (
7
6
4
)
Pr
ds
fro
d
ive
i
t
tu
+
oc
ee
m
s
re
s		 0 1
3
8		 2
5		 1
4
6
Ac
is
i
t
ion
d
inv
tm
ts
t o
f
d
ive
t
i
tu
q
u
s a
n
es
en
ne
s
re
s
=
,		 (
7
9
)		 (
2
4
8
)		 (
1
3
6
)		 (
6
1
8
)
(
)
Re
ts
Pr
ds
p
ay
me
n
oc
ee		 - 1
3
1		 (
)
5
0		 -
Ac
is
i
ion
d
inv
(
),
f
d
ive
i
t
tm
ts
t
t o
t
tu
q
u
s a
n
es
en
ne
ne
s
re
s
=		 (
7
9
)		 (
3
7
9
)		 (
1
8
6
)		 (
6
1
8
)
Pa
ien
l
in
ics
F
isc
l
Ye
2
0
1
0
t
ts
tre
tm
ts
a
en
c
a
ar
-
,
,		 C
l
in
ics		 Pa
t
ien
ts		 Tr
ts in
tm
ea
en
i
l
l
ion
m
No
h
Am
ica
t
r
er		 1,
8
2
3		 1
3
7,
6
8
9		 2
0.
8
5
Gr
t
h
in
%
ow		 2 4 5
In
te
t
ion
l
rn
a
a		 9
3
4		 6,
9
9
7
5		 1
0.
8
2
Gr
t
h
in
%
ow		 2
1		 2
1		 1
3
Eu
ro
p
e		 4
9
9		 3
8,
0
6
1		 5.
4
5
La
in
Am
ica
t
er		 1
9
3		 2
2,
4
7
1		 3.
3
9
As
ia-
Pa
i
f
ic
c		 2
4
2		 1
6,
4
2
7		 1.
9
7
T
O
T
A
L		 2,
7
5
7		 2
1
4,
6
4
8		 3
1.
6
7
Gr
h
in
%
t
ow		 8 1
0		 8

All numbers are in US\$ millions

© I Analyst Conference | Full Year 2010 31

Attachment 3

Reconciliation of non-US-GAAP financial measures to most comparable US-GAAP measure

All numbers are in US\$ millions

De
b
t		 F
Y
2
0
1
0		 F
Y
2
0
0
9		 F
Y
2
0
0
8		 F
Y
2
0
0
7		 F
Y
2
0
0
6		 F
Y
2
0
0
5
S
(
/
)
ho
t
te
bo
ing
inc
l.
A
R
r
rm
rro
w
s
p
ro
g
ra
m		 6
7
1		 3
1
6		 6
8
4		 2
1
7		 3
3
1		 1
5
1
S
fro
ho
t
te
bo
ing
la
te
d
t
ies
+
r
rm
rro
w
m
re
p
ar		 1
0		 1
0		 1 2 5 1
9
Cu
t p
t
ion
f
lon
te
de
b
t a
d
+
rre
n
or
o
g-
rm
n
i
ta
l
lea
b
l
ig
t
ion
ca
p
se
o
a
s		 2
6
4		 1
5
8		 4
5
5		 8
5		 1
6
0		 1
2
6
Cu
t p
t
ion
f
Tr
t
Pr
fe
d
Se
i
t
ies
+
rre
n
or
o
us
e
rre
cu
r		 - - - 6
7
0		 - -
Lo
-te
de
b
t a
d c
i
ta
l
lea
b
l
ig
t
ion
+
ng
rm
n
ap
se
o
a
s
les
t p
t
ion
s c
ur
re
n
or		 4,
3
1
0		 4,
4
2
8		 3,
9
5
7		 4,
0
0
4		 3,
8
2
9		 7
0
7
Tr
t
Pr
fe
d
Se
i
t
ies
les
t p
t
ion
+
us
e
rre
cu
r
s c
ur
re
n
or		 6
2
5		 6
5
6		 6
4
1		 6
6
4		 1,
2
5
4		 1,
1
8
8
T
O
T
A
L
de
b
t		 5,
8
8
0		 5,
5
6
8		 5,
7
3
8		 5,
6
4
2		 5,
5
7
9		 2,
1
9
1
E
B
I
T
D
A		 F
Y
2
0
1
0		 F
Y
2
0
0
9		 F
Y
2
0
0
8		 F
Y
2
0
0
7		 F
Y
2
0
0
6		 F
Y
2
0
0
5
La
t
tw
lve
t
h o
t
ing
inc
(
E
B
I
T
)
s
e
m
on
p
er
a
om
e		 1,
9
2
4		 1,
7
5
6		 1,
6
7
2		 1,
5
8
0		 1,
3
6
7		 9
3
9
La
lve
h
de
ia
ion
d a
iza
ion
t
tw
t
t
t
t
+
s
e
m
on
p
re
c
a
n
mo
r		 5
0
3		 4
5
7		 4
1
6		 3
6
3		 3
2
6		 2
5
1
No
h c
ha
+
n-
ca
s
rg
es		 4
5		 0
5		 4
4		 4
1		 3
5		 1
4
(
ize
)
E
B
I
T
D
A
l
d
an
nu
a		 2,
4
7
2		 2,
2
6
3		 2,
1
3
2		 1,
9
8
4		 1,
7
2
8		 1,
2
0
4
/
To
l
De
b
E
B
I
T
D
A
ta
t		 2.
3
8		 2.
4
6		 2.
6
9		 2.
8
4		 3.
2
3		 1.
8
2

© I Analyst Conference | Full Year 2010 32

Contacts

Fresenius Medical Care

Investor RelationsElse-Kröner-Str. 161352 Bad Homburg v.d.H.

T
i
k
c
e
r
:		 F
M
E
F
M
S
(
N
Y
S
E
)
o
r
W
K
N
:		 8
8
0
5
7
5
I
S
I
N
:		 D
E
0
0
0
5
7
8
5
8
0
0
2
  • X Oliver Maier │Head of Investor Relations and Corporate Communications Tel: +49-(0) 6172 – 609 – 2601 Email: [email protected]
  • X Gerrit Jost Tel: +49-(0) 6172 – 609 – 5216 Email: [email protected]
  • X Terry Morris Tel: +1- 800 – 948 – 2538Email: [email protected]

Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

Fiscal Year 2010

Analyst Conference February 23, 2011

More from Fresenius Medical Care AG & Co. KGaA

Regulatory Filings 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.